Navigation Links
Isolagen to Present at the JMP Securities Healthcare Focus Conference
Date:10/3/2008

ing of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in Item 1A. "Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
2. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
3. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
5. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
6. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
7. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
8. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
9. ViroPharma to Present at Three October Healthcare Conferences
10. BioCryst to Present at the JMP Healthcare Focus Conference
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... IN (PRWEB) July 25, 2014 At ... (FAA) has granted a 60-day extension for the public ... the Special Rule for Model Aircraft established by Congress ... of 2012. The 60-day extension establishes the new deadline ... United States Department of Transportation/FAA notice published in the ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Inc. (Amex:,SGN) announced that it has filed its Form ... of trading of its common stock,on the American Stock ... trade on AMEX will be Friday, September 12, 2008.,Signalife ... for,quotation on both the Over-The-Counter Bulletin Board and the ...
... Takeda San Francisco Inc.,announced today that Gregory Landes, ... antibody research. Dr. Landes will be responsible for,directing ... Takeda,s antibody IND engine and center of excellence ... experience in the biopharmaceutical,industry and is a great ...
... Sept. 8 NovaVision today announced,that the company ... AdvaMed,2008: The MedTech Conference (http://www.advamed2008.com ), on ... the presentation, which falls in the "Next Generation" ... officer of,NovaVision, will address the increasing use of ...
Cached Biology Technology:Signalife Announces Anticipated Date of Transition to OTCBB 2Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research 2NovaVision CEO Named Presenter at the AdvaMed 2008 Conference 2
(Date:7/24/2014)... new study has identified two factors that characterize ... the production of highly qualified physics teachers. Specifically, ... champion physics teacher education in combination with institutional ... remain viable. Science, Technology, Engineering and Math (STEM) ... the study points the way for institutions seeking ...
(Date:7/24/2014)... 2014 Some sticky research out of York University ... certain species of toxic grass fungus: moose saliva (yes ... Biology Letters , "Ungulate saliva inhibits a grassendophyte mutualism" ... red fescue grass (which hosts a fungus called epichlo ... fungus growth and less toxicity. , "Plants have evolved ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva University ... Foundation for Parkinson,s Research to translate a basic science ... discovery project will test chemical compounds on a newly ... that acts on an underlying cause of the disease. ... people manage their symptoms, we are eager to stop ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... of the most recent, popular supplements for athletes looking to ... acid called L-arginine. The reason for its popularity ... physiology. "First, L-arginine is a precursor for nitric oxide ... may aid the delivery of important nutrients to working muscles ...
... published this month in the Journal of the American ... Science Center at San Antonio have pinpointed the cancer-fighting potential ... Susan Mooberry, Ph.D., leader of the Experimental Development Therapeutics Program ... of pharmacology at the UT Health Science Center, has been ...
... Researchers at King,s College London have discovered how one ... pave the way for less harmful pain relief medications to ... in the US and Asia as acetaminophen, is a widely-used ... as cold and flu remedies. Although discovered in the ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3Bat plant could give some cancers a devil of a time 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 3